ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

PLSE Pulse Biosciences Inc

11.40
-0.45 (-3.80%)
Jun 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 102,841
Bid Price 11.09
Ask Price 11.81
News -
Day High 11.70

Low
3.78

52 Week Range

High
14.96

Day Low 11.23
Company Name Stock Ticker Symbol Market Type
Pulse Biosciences Inc PLSE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.45 -3.80% 11.40 20:00:00
Open Price Low Price High Price Close Price Prev Close
11.70 11.23 11.70 11.40 11.85
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,693 102,841 $ 11.48 $ 1,180,627 - 3.78 - 14.96
Last Trade Time Type Quantity Stock Price Currency
19:28:14 1 $ 11.40 USD

Pulse Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
625.8M 54.99M - 0 -42.21M -0.77 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pulse Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PLSE Message Board. Create One! See More Posts on PLSE Message Board See More Message Board Posts

Historical PLSE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.0614.4011.2312.86184,230-0.66-5.47%
1 Month8.5714.968.5712.61315,0052.8333.02%
3 Months8.5714.966.5959.89225,9262.8333.02%
6 Months9.8414.966.59510.01221,6771.5615.85%
1 Year6.3714.963.788.42215,8095.0378.96%
3 Years17.0629.161.187.29162,745-5.66-33.18%
5 Years12.5745.821.189.79133,344-1.17-9.31%

Pulse Biosciences Description

Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems.

Your Recent History

Delayed Upgrade Clock